Brief: Viatris And Theravance Biopharma Announce Positive Top-Line Results From Yupelri (Revefenacin) Phase III Trial
13/11/2023 14:57
Nov 13 (Reuters) - Theravance Biopharma Inc TBPH.O :
* VIATRIS AND THERAVANCE BIOPHARMA ANNOUNCE POSITIVE
TOP-LINE
RESULTS FROM YUPELRI® (REVEFENACIN) PHASE III TRIAL IN CHINA FOR
THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Source text for Eikon: ID:nPn98hCFha
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy